Table 2. Percentage Growth of Cancer Cells Treated with Compounds 14a–e at a Dose of 10 μM.
| compound
code |
|||||
|---|---|---|---|---|---|
| cell lines | 14a | 14b | 14c | 14d | 14e |
| Leukemia | |||||
| CCRF-CEM | 71.50 | 68.19 | 100.36 | 95.61 | 71.38 |
| HL-60 (TB) | 85.63 | 74.17 | 98.35 | 99.62 | 86.62 |
| K-562 | 40.44 | 33.54 | 88.12 | 98.34 | 49.72 |
| MOLT-4 | 53.06 | 37.57 | 90.22 | 83.28 | 56.82 |
| RPMI-8226 | 62.07 | 55.63 | 91.70 | 83.11 | 55.71 |
| SR | 54.98 | 46.71 | 94.33 | 110.60 | 63.03 |
| Non-Small Cell Lung Cancer | |||||
| A549/ATCC | 49.62 | 41.79 | 90.47 | 80.73 | 50.05 |
| EKVX | 62.12 | 55.67 | 94.73 | 86.66 | 62.59 |
| HOP-62 | 74.00 | 69.46 | 93.10 | 96.48 | 80.65 |
| HOP-92 | 74.00 | 63.35 | 80.32 | 77.50 | 69.19 |
| NCI-H226 | 78.73 | 70.15 | 91.57 | 85.55 | 75.18 |
| NCI-H23 | 73.57 | 68.08 | 89.45 | 92.28 | 80.01 |
| NCI-H322M | 94.03 | 88.49 | 104.84 | 87.93 | 94.89 |
| NCI-H460 | 66.60 | 55.15 | 101.26 | 96.83 | 61.12 |
| NCI-H522 | 64.00 | 58.49 | 85.49 | 74.65 | 60.43 |
| Colon Cancer | |||||
| COLO 205 | 62.68 | 62.49 | 102.44 | 96.67 | 76.94 |
| HCC-2998 | 91.33 | 84.28 | 100.45 | 102.09 | 94.37 |
| HCT-116 | 43.56 | 40.67 | 97.26 | 94.53 | 56.08 |
| HCT-15 | 61.26 | 55.74 | 96.94 | 89.11 | 63.64 |
| HT29 | 48.08 | 40.15 | 98.50 | 85.26 | 51.02 |
| KM12 | 66.51 | 51.38 | 93.75 | 87.36 | 60.63 |
| SW-620 | 71.04 | 65.24 | 96.16 | 99.75 | 73.74 |
| CNS Cancer | |||||
| SF-268 | 65.13 | 60.60 | 92.02 | 75.05 | 65.07 |
| SF-295 | 67.97 | 61.48 | 90.14 | 89.53 | 59.94 |
| SF-539 | 85.06 | 92.12 | 98.89 | 91.03 | 81.48 |
| SNB-19 | 69.72 | 67.47 | 86.60 | 81.32 | 70.80 |
| SNB-75 | 52.87 | 49.29 | 66.80 | 75.35 | 50.69 |
| U251 | 71.61 | 62.43 | 96.50 | 85.96 | 68.25 |
| Melanoma | |||||
| LOX IMVI | 81.68 | 69.19 | 87.65 | 87.59 | 75.58 |
| MALME-3M | 84.71 | 78.68 | 96.67 | 93.54 | 82.24 |
| M14 | 73.67 | 70.35 | 87.71 | 105.17 | 68.36 |
| MDA-MB-435 | 77.39 | 67.56 | 96.35 | 96.33 | 70.59 |
| SK-MEL-2 | 87.53 | 90.99 | 99.01 | 88.49 | 85.77 |
| SK-MEL-28 | 99.31 | 99.47 | 113.51 | 100.52 | 102.38 |
| SK-MEL-5 | 91.31 | 85.03 | 98.70 | 93.57 | 80.91 |
| UACC-257 | 86.29 | 79.50 | 99.11 | 87.35 | 84.56 |
| UACC-62 | 57.28 | 53.14 | 74.33 | 81.49 | 54.50 |
| Ovarian Cancer | |||||
| IGROV1 | 58.20 | 47.30 | 83.72 | 93.05 | 49.15 |
| OVCAR-3 | 80.46 | 66.91 | 102.30 | 92.51 | 72.45 |
| OVCAR-4 | 72.50 | 64.86 | 83.50 | 90.29 | 65.48 |
| OVCAR-5 | 79.86 | 78.10 | 99.24 | 90.00 | 85.94 |
| OVCAR-8 | 70.10 | 63.16 | 93.55 | 90.19 | 68.88 |
| NCI/ADR-RES | 58.12 | 55.63 | 87.31 | 90.90 | 61.98 |
| SK-OV-3 | 71.45 | 73.10 | 96.74 | 85.97 | 78.65 |
| Renal Cancer | |||||
| 786–0 | 77.49 | 75.83 | 101.89 | 101.14 | 83.95 |
| A498 | 95.62 | 64.76 | 107.42 | 77.00 | 80.27 |
| ACHN | 73.63 | 69.39 | 92.15 | 98.11 | 70.09 |
| CAKI-1 | 45.04 | 40.58 | 68.86 | 75.97 | 46.05 |
| RXF 393 | 63.02 | 51.07 | 87.44 | 81.82 | 65.70 |
| SN12C | 66.79 | 40.76 | 92.66 | 85.18 | 71.35 |
| TK-10 | 95.84 | 90.62 | 104.27 | 81.46 | 97.60 |
| UO-31 | 38.17 | 34.52 | 56.48 | 79.07 | 40.43 |
| Prostate Cancer | |||||
| PC-3 | 41.79 | 32.66 | 73.03 | - | 34.66 |
| DU-145 | 86.15 | 81.52 | 102.88 | 95.82 | 77.79 |
| Breast Cancer | |||||
| MCF7 | 56.72 | 46.42 | 101.02 | 93.03 | 52.46 |
| MDA-MB-231/ATCC | 86.25 | 76.78 | 93.62 | 84.15 | 76.02 |
| HS 578T | 83.25 | 79.67 | 89.96 | 83.98 | 78.74 |
| BT-549 | 102.10 | 91.99 | 103.03 | 95.83 | 95.00 |
| T-47D | 48.47 | 45.84 | 90.26 | 70.47 | 46.98 |
| MDA-MB-468 | 84.16 | 82.10 | 111.00 | 79.61 | 72.04 |
| mean % growth | 70.59 | 63.79 | 93.11 | 89.01 | 69.44 |